Company Description
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States.
Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.
The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Eric Poma |
Contact Details
Address: 4475 Executive Drive, Suite 200 San Diego, California 92121 United States | |
| Phone | 858 794 9600 |
| Website | calidibio.com |
Stock Details
| Ticker Symbol | CLDI |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001855485 |
| CUSIP Number | 320703309 |
| ISIN Number | US3207033099 |
| Employer ID | 86-2967193 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Allan J. Camaisa | Chief Executive Officer and Chairman of the Board |
| Andrew C. Jackson | Chief Financial Officer |
| Wendy Pizarro Campbell Esq. | Chief Legal, Chief Corporate Dev, Chief Diversity and Corp Secretary |
| Dr. Boris Minev M.D., Ph.D. | President of Medical and Scientific Affairs |
| Dr. Antonio Fernandez Santidrian Ph.D., Pharm.D. | Head of Technical Operations and Chief Scientific Officer |
| Guy Travis Clifton M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | 8-K | Current Report |
| Apr 10, 2025 | 8-K | Current Report |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 424B5 | Filing |
| Mar 10, 2025 | 8-K | Current Report |
| Feb 10, 2025 | 8-K/A | [Amend] Current report |
| Feb 7, 2025 | EFFECT | Notice of Effectiveness |
| Feb 5, 2025 | 424B5 | Filing |